TORTORA, GIAMPAOLO
TORTORA, GIAMPAOLO
DIPARTIMENTO DI MEDICINA
A novel modified CpG agonist of TLR-9 inhibits EGF receptor signalling and synergistically enhances antitumor activity of cetuximab and irinotecan eradicating colon cancer xenografts
2005-01-01 Tortora, Giampaolo; Bianco, R.; Caputo, R.; D'Armiento, F.; Melisi, Davide; Bianco, A. R.; De Placido, S.; Agrawal, S.; Ciardiello, F.; Damiano, V.
A novel modified CpG inhibits EGF receptor signalling and synergistically enhances antitumor activity of cetuximab and irinotecan in colon cancer xenografts.
2005-01-01 Tortora, Giampaolo; Bianco, R.; Caputo, R.; D'Armiento, F.; Melisi, Davide; Bianco, A. R.; De Placido, S.; Agrawal, S.; Ciardiello, F.; Damiano, V.
A selective cyclooxygenase-2 inhibitor combined with the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 ('Iressa') and protein kinase A antisense causes cooperative tumor growth inhibition after oral administration
2002-01-01 Tortora, Giampaolo; Caputo, R.; Damiano, V.; Melisi, Davide; Bianco, R.; Fontanini, G.; Bianco, A. R.; Ciardiello, F.
Cooperative antitumor and antiangiogenic activity after oral administration of a novel taxane, an antisense targeting protein kinase A and the EGF receptor inhibitor Iressa
2001-01-01 Damiano, V.; Caputo, R.; Fontanini, G.; Faviana, P.; Melisi, Davide; De Placido, S.; Zunino, F.; Bianco, A. R.; Ciardiello, F.; Tortora, Giampaolo
EGFR TKI induction of detectable signals in lung cancer
2008-01-01 A., Zannetti; F., Iommelli; R., Fonti; A., Papaccioli; J., Sommella; A., Lettieri; R., Bianco; Tortora, Giampaolo; M., Salvatore; S., DEL VECCHIO
ESGAR 2016 Book of Abstracts
2016-01-01 DE ROBERTIS LOMBARDI, Riccardo; D'Onofrio, Mirko; Ortolani, Silvia; Tinazzi Martini, P.; Cingarlini, Sara; Butturini, Giovanni; Gobbo, Stefano; Capelli, Paola; Girelli, Roberta; Regi, Paolo; Tortora, Giampaolo; Pederzoli, Paolo; Scarpa, Aldo
Gefitinib ('Iressa, ZD1839') and a second generation antisense targeting murine double minute 2 (Mdm2) synergistically inhibit tumor growth and angiogenesis in hormone-refractory prostate cancer
2003-01-01 Bianco, R.; Caputo, R.; Caputo, R.; Damiano, V.; Melisi, Davide; Bianco, R.; Ciardiello, F.; Tortora, Giampaolo
Histogram analysis of ADC maps: assessment of intra-tumoral heterogeneity and correlation with the biological behavior of pancreatic neuroendocrine neoplasms
2017-01-01 de robertis, R.; cardobi, N.; maris, B.; tinazzi martini, P.; ortolani, S.; cingarlini, S.; butturini, G.; gobbo, S.; landoni, L.; fiorini, P.; tortora, G.; scarpa, A.; d‘onofrio, M.
Human cancer cells with acquired resistance to anti-EGFR therapy are inhibited by VEGF- and EGFR-receptors tyrosine kinase inhibitor ZD6474
2004-01-01 Bianco, R.; Caputo, R.; Caputo, R.; Damiano, V.; Troiani, T.; Melisi, Davide; Bianco, A. R.; Tortora, Giampaolo; Ciardiello, F.
Imaging of lung cancer resistance to EGFR tyrosine kinase inhibitors trough Bcl-2/Bcl-xL modulation of inositol trisphosphate receptor type 3
2008-01-01 A., Zannetti; F., Iommelli; R., Fonti; A., Papaccioli; J., Sommella; A., Lettieri; R., Bianco; Tortora, Giampaolo; M., Salvatore; S., DEL VECCHIO
Normal Tissue Perfusion Changes During Everolimus Treatment: Preliminary Results from a Functional Vascular Study
2014-01-01 Vallerio, P; Cingarlini, Sara; Trentin, C; Grego, E; D'Onofrio, Mirko; Butturini, Giovanni; Davi, Mv; Scarpa, Aldo; Capelli, Paola; Ruzzenente, Andrea; Marchi, Sd; Tortora, Giampaolo
Novel anticancer drugs TLR9 agonists interfere with EGFR signaling and potently synergies with EGFR inhibitors and with bevacizumab in wild type and cetuximab-resistant colon cancer xenografts
2007-01-01 Tortora, Giampaolo; Caputo, R.; Bianco, R.; Garofalo, S.; Racioppi, L.; De Placido, S.; Ciardiello, F.; Agrawal, S.; Melisi, Davide; Damiano, V.
Novel Toll-like receptor 9 (TLR9) agonist IMO inhibits tumor growth and cooperates with cetuximab in K-Ras mutant colon and pancreatic cancer
2009-01-01 Rosa, R.; Melisi, Davide; Damiano, V.; Bianco, R.; Gelardi, T.; Garofalo, S.; Formisano, L.; Nappi, ; Marciano, R.; Tortora, Giampaolo
Pancreatic neuroendocrine neoplasms: MRI features and correlation with their histological grade
2016-01-01 DE ROBERTIS LOMBARDI, Riccardo; D'Onofrio, Mirko; Ortolani, Silvia; Tinazzi Martini, P.; Cingarlini, Sara; Butturini, G.; Gobbo, S.; Capelli, Paola; Girelli, R.; Regi, Paolo; Tortora, Giampaolo; Pederzoli, Paolo; Scarpa, Aldo
Perfusion Changes in Liver Metastases (LM) from Pancreatic Neuroendocrine Tumors (PanNETs) during Everolimus (E) Treatment: Update of Perfusion CT (P-CT) Study
2015-01-01 Ortolani, S.; De Robertis, R.; D'Onofrio, M.; Cingarlini, S.; Crosara, S.; Butturini, G.; Ruzzenente, A.; Davi, M.; Vallerio, P.; Trentin, C.; Tortora, G.; Scarpa, A.; Bassi, C.; Pozzi Mucelli, R.
Potential role of RICTOR copy number gain (CNG) as a key biomarker of mTOR activity: A comprehensive preclinical analysis in squamous cell lung cancer (SQLC) models
2018-01-01 Gkountakos, A; Pilotto, S; Simbolo, M; Vicentini, C; Mafficini, A; Del Curatolo, A; Scarpa, A; Tortora, G; Corbo, V; Bria, E
Preliminary results of PRINCiPe (predictors of resistance to immunotherapy with nivolumab [NIV]) study in advanced pretreated non-small cell lung cancer (APNSCLC), investigating the role of an immune genomic signature (IGS) including JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2 alterations
2018-01-01 Pilotto, S; Grizzi, G; Sperduti, I; Simbolo, M; Vicentini, C; Caliò, A; Caccese, M; Mafficini, A; Carbognin, L; Corbo, V; Gkountakos, A; Santo, A; Infante, M; Brunelli, M; Scarpa, A; Tortora, G; Bria, E
R1507, the human monoclonal antibody targeting the Insulin-like Growth Factor Receptor (IGF-1R), in combination with cetuximab can reverse acquired resistance to cetuximab in pancreatic and colon cancer models
2010-01-01 Melisi, Davide; Rosa, R.; Bianco, R.; Carmine, C.; Tortora, Giampaolo; Budillon, A.; Abbuzzese, J. L.; Chiao, P. J.; Javle, M.
Streptozotocin/5-Fluorouracil (STZ/5FU) Chemotherapy in G1-G2 Pancreatic Neuroendocrine Tumors (pNETs): Single Institution Experience
2014-01-01 Cingarlini, Sara; Trentin, C; Ottolani, S; Grego, E; D'Onofrio, Mirko; Scarpa, Aldo; Ruzzenente, Andrea; Butturini, Giovanni; Capelli, Paola; Tortora, Giampaolo
Targeting transforming growth factor beta (TGFbeta) type I receptor kinase activity: a therapeutic approach to suppress metastatic processes in human pancreatic cancer (HPC)
2007-01-01 Melisi, Davide; Ishiyama, S.; Sclabas, G. M.; Tortora, Giampaolo; Abbruzzese, J. L.; Chaio, P. J.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A novel modified CpG agonist of TLR-9 inhibits EGF receptor signalling and synergistically enhances antitumor activity of cetuximab and irinotecan eradicating colon cancer xenografts | 1-gen-2005 | Tortora, Giampaolo; Bianco, R.; Caputo, R.; D'Armiento, F.; Melisi, Davide; Bianco, A. R.; De Placido, S.; Agrawal, S.; Ciardiello, F.; Damiano, V. | |
| A novel modified CpG inhibits EGF receptor signalling and synergistically enhances antitumor activity of cetuximab and irinotecan in colon cancer xenografts. | 1-gen-2005 | Tortora, Giampaolo; Bianco, R.; Caputo, R.; D'Armiento, F.; Melisi, Davide; Bianco, A. R.; De Placido, S.; Agrawal, S.; Ciardiello, F.; Damiano, V. | |
| A selective cyclooxygenase-2 inhibitor combined with the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 ('Iressa') and protein kinase A antisense causes cooperative tumor growth inhibition after oral administration | 1-gen-2002 | Tortora, Giampaolo; Caputo, R.; Damiano, V.; Melisi, Davide; Bianco, R.; Fontanini, G.; Bianco, A. R.; Ciardiello, F. | |
| Cooperative antitumor and antiangiogenic activity after oral administration of a novel taxane, an antisense targeting protein kinase A and the EGF receptor inhibitor Iressa | 1-gen-2001 | Damiano, V.; Caputo, R.; Fontanini, G.; Faviana, P.; Melisi, Davide; De Placido, S.; Zunino, F.; Bianco, A. R.; Ciardiello, F.; Tortora, Giampaolo | |
| EGFR TKI induction of detectable signals in lung cancer | 1-gen-2008 | A., Zannetti; F., Iommelli; R., Fonti; A., Papaccioli; J., Sommella; A., Lettieri; R., Bianco; Tortora, Giampaolo; M., Salvatore; S., DEL VECCHIO | |
| ESGAR 2016 Book of Abstracts | 1-gen-2016 | DE ROBERTIS LOMBARDI, Riccardo; D'Onofrio, Mirko; Ortolani, Silvia; Tinazzi Martini, P.; Cingarlini, Sara; Butturini, Giovanni; Gobbo, Stefano; Capelli, Paola; Girelli, Roberta; Regi, Paolo; Tortora, Giampaolo; Pederzoli, Paolo; Scarpa, Aldo | |
| Gefitinib ('Iressa, ZD1839') and a second generation antisense targeting murine double minute 2 (Mdm2) synergistically inhibit tumor growth and angiogenesis in hormone-refractory prostate cancer | 1-gen-2003 | Bianco, R.; Caputo, R.; Caputo, R.; Damiano, V.; Melisi, Davide; Bianco, R.; Ciardiello, F.; Tortora, Giampaolo | |
| Histogram analysis of ADC maps: assessment of intra-tumoral heterogeneity and correlation with the biological behavior of pancreatic neuroendocrine neoplasms | 1-gen-2017 | de robertis, R.; cardobi, N.; maris, B.; tinazzi martini, P.; ortolani, S.; cingarlini, S.; butturini, G.; gobbo, S.; landoni, L.; fiorini, P.; tortora, G.; scarpa, A.; d‘onofrio, M. | |
| Human cancer cells with acquired resistance to anti-EGFR therapy are inhibited by VEGF- and EGFR-receptors tyrosine kinase inhibitor ZD6474 | 1-gen-2004 | Bianco, R.; Caputo, R.; Caputo, R.; Damiano, V.; Troiani, T.; Melisi, Davide; Bianco, A. R.; Tortora, Giampaolo; Ciardiello, F. | |
| Imaging of lung cancer resistance to EGFR tyrosine kinase inhibitors trough Bcl-2/Bcl-xL modulation of inositol trisphosphate receptor type 3 | 1-gen-2008 | A., Zannetti; F., Iommelli; R., Fonti; A., Papaccioli; J., Sommella; A., Lettieri; R., Bianco; Tortora, Giampaolo; M., Salvatore; S., DEL VECCHIO | |
| Normal Tissue Perfusion Changes During Everolimus Treatment: Preliminary Results from a Functional Vascular Study | 1-gen-2014 | Vallerio, P; Cingarlini, Sara; Trentin, C; Grego, E; D'Onofrio, Mirko; Butturini, Giovanni; Davi, Mv; Scarpa, Aldo; Capelli, Paola; Ruzzenente, Andrea; Marchi, Sd; Tortora, Giampaolo | |
| Novel anticancer drugs TLR9 agonists interfere with EGFR signaling and potently synergies with EGFR inhibitors and with bevacizumab in wild type and cetuximab-resistant colon cancer xenografts | 1-gen-2007 | Tortora, Giampaolo; Caputo, R.; Bianco, R.; Garofalo, S.; Racioppi, L.; De Placido, S.; Ciardiello, F.; Agrawal, S.; Melisi, Davide; Damiano, V. | |
| Novel Toll-like receptor 9 (TLR9) agonist IMO inhibits tumor growth and cooperates with cetuximab in K-Ras mutant colon and pancreatic cancer | 1-gen-2009 | Rosa, R.; Melisi, Davide; Damiano, V.; Bianco, R.; Gelardi, T.; Garofalo, S.; Formisano, L.; Nappi, ; Marciano, R.; Tortora, Giampaolo | |
| Pancreatic neuroendocrine neoplasms: MRI features and correlation with their histological grade | 1-gen-2016 | DE ROBERTIS LOMBARDI, Riccardo; D'Onofrio, Mirko; Ortolani, Silvia; Tinazzi Martini, P.; Cingarlini, Sara; Butturini, G.; Gobbo, S.; Capelli, Paola; Girelli, R.; Regi, Paolo; Tortora, Giampaolo; Pederzoli, Paolo; Scarpa, Aldo | |
| Perfusion Changes in Liver Metastases (LM) from Pancreatic Neuroendocrine Tumors (PanNETs) during Everolimus (E) Treatment: Update of Perfusion CT (P-CT) Study | 1-gen-2015 | Ortolani, S.; De Robertis, R.; D'Onofrio, M.; Cingarlini, S.; Crosara, S.; Butturini, G.; Ruzzenente, A.; Davi, M.; Vallerio, P.; Trentin, C.; Tortora, G.; Scarpa, A.; Bassi, C.; Pozzi Mucelli, R. | |
| Potential role of RICTOR copy number gain (CNG) as a key biomarker of mTOR activity: A comprehensive preclinical analysis in squamous cell lung cancer (SQLC) models | 1-gen-2018 | Gkountakos, A; Pilotto, S; Simbolo, M; Vicentini, C; Mafficini, A; Del Curatolo, A; Scarpa, A; Tortora, G; Corbo, V; Bria, E | |
| Preliminary results of PRINCiPe (predictors of resistance to immunotherapy with nivolumab [NIV]) study in advanced pretreated non-small cell lung cancer (APNSCLC), investigating the role of an immune genomic signature (IGS) including JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2 alterations | 1-gen-2018 | Pilotto, S; Grizzi, G; Sperduti, I; Simbolo, M; Vicentini, C; Caliò, A; Caccese, M; Mafficini, A; Carbognin, L; Corbo, V; Gkountakos, A; Santo, A; Infante, M; Brunelli, M; Scarpa, A; Tortora, G; Bria, E | |
| R1507, the human monoclonal antibody targeting the Insulin-like Growth Factor Receptor (IGF-1R), in combination with cetuximab can reverse acquired resistance to cetuximab in pancreatic and colon cancer models | 1-gen-2010 | Melisi, Davide; Rosa, R.; Bianco, R.; Carmine, C.; Tortora, Giampaolo; Budillon, A.; Abbuzzese, J. L.; Chiao, P. J.; Javle, M. | |
| Streptozotocin/5-Fluorouracil (STZ/5FU) Chemotherapy in G1-G2 Pancreatic Neuroendocrine Tumors (pNETs): Single Institution Experience | 1-gen-2014 | Cingarlini, Sara; Trentin, C; Ottolani, S; Grego, E; D'Onofrio, Mirko; Scarpa, Aldo; Ruzzenente, Andrea; Butturini, Giovanni; Capelli, Paola; Tortora, Giampaolo | |
| Targeting transforming growth factor beta (TGFbeta) type I receptor kinase activity: a therapeutic approach to suppress metastatic processes in human pancreatic cancer (HPC) | 1-gen-2007 | Melisi, Davide; Ishiyama, S.; Sclabas, G. M.; Tortora, Giampaolo; Abbruzzese, J. L.; Chaio, P. J. |